![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
AMSTERDAM, THE NETHERLANDS, and BRIDGEWATER, NJ -- (Marketwire) -- 01/31/11 -- Eurand N.V. (NASDAQ: EURX) and Axcan Holdings, Inc. announced the extension of the expiration date of the offer of...
AMSTERDAM, THE NETHERLANDS and BRIDGEWATER, NJ -- (Marketwire) -- 01/20/11 -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, and Axcan Holdings, Inc., a leading...
AMSTERDAM, THE NETHERLANDS and BRIDGEWATER, NJ -- (Marketwire) -- 01/19/11 -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, and Axcan Holdings, Inc., a leading...
MILAN, ITALY, and ZURICH, SWITZERLAND -- (Marketwire) -- 01/12/11 -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, and Nycomed, a privately owned global pharmaceutical...
AMSTERDAM, THE NETHERLANDS and BRIDGEWATER, NJ -- (Marketwire) -- 12/01/10 -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, and Axcan Holdings, Inc., a leading...
AMSTERDAM, THE NETHERLANDS -- (Marketwire) -- 11/05/10 -- Eurand N.V. (NASDAQ: EURX) Recent Highlights: Record revenues of EUR 41.7 million ($56.7 million), up 36% from the third quarter of 2009...
YARDLEY, PA -- (Marketwire) -- 11/01/10 -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, is scheduled to participate in the following upcoming investor conferences:...
AMSTERDAM, THE NETHERLANDS -- (Marketwire) -- 10/21/10 -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, will host a conference call on Friday, November 5, 2010 at 8:30...
YARDLEY, PA -- (Marketwire) -- 10/21/10 -- Eurand Pharmaceuticals, Inc., a subsidiary of global specialty pharmaceutical company Eurand N.V. (NASDAQ: EURX), today announced additional data from a...
PHILADELPHIA, PA -- (Marketwire) -- 09/24/10 -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, announced today that Gearóid Faherty, Chairman and Chief Executive Officer...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions